BACKGROUND Incident heart failure (HF) is increased in persons with human immunodeficiency virus (PHIV).
In animal models, PIs are associated with an increase in transforming growth factor beta-1, leading to myocardial fibrosis and impaired cardiac function (7, 8) . Furthermore, echocardiographic studies in PHIV without known cardiovascular (CV) disease have shown that PIs are associated with left ventricular hypertrophy (9) . It is therefore plausible that the use of PI-based ART may be associated with adverse outcomes in PHIV with heart failure (HF). Determination of whether PI-based ART regimens affect HF outcomes may be important for the following reasons: 1) the risk of incident HF is increased more than 2-fold among PHIV (10, 11) and, as the group of PHIV ages, rates of incident HF are projected to increase dramatically (12); and 2) once HF is established in HIV infection, there is a 4-fold increased risk of being admitted for decompensated HF and a 3-fold increase in CV mortality (13) . Therefore, we aimed to study the association between PI use and CV outcomes in PHIV with HF. We hypothesized that PI-based therapy would be associated with adverse CV changes and adverse outcomes in HF. or intensification of treatment specifically for HF (14) . Values are n (%), mean AE SD, or median (interquartile range). Bold p values are statistically significant. *Duration of HIV is in years. †Duration of untreated HIV is the duration before starting ART after the diagnosis in days.
METHODS
HFrEF ¼ heart failure with reduced ejection fraction; other abbreviations as in Table 1 . Values are n (%), mean AE SD, or median (interquartile range). Bold p values are statistically significant. *Duration of HIV is in years. †Duration of untreated HIV is the duration before starting ART after the diagnosis in days.
HFpEF ¼ heart failure with preserved ejection fraction; other abbreviations as in Table 1 . CI ¼ confidence interval; other abbreviations as in Table 1 . Table 3 ). †High school diploma, GED, or higher.
Abbreviations as in Tables 1 and 4 .
Alvi et al. copies/ml (range <50 to 3,000,457 copies/ml had an NPI.
OUTCOMES. C V m o r t a l i t y .
In the entire cohort of 394 patients, there were 93 CV deaths (23%) over 2 years of follow-up. The CV mortality rate was higher among PHIV hospitalized with HF who were taking a PI versus an NPI (35% vs. 17%; p < 0.001) (Figure 2A ).
Similar findings of increased CV mortality were noted when the cohort was stratified by the type of HF (HFrEF, HFpEF, and HFbEF). Specifically, among the PHIV hospitalized with HFrEF, the CV mortality rate was higher among the individuals who were taking a PI versus an NPI (36% vs. 21%; p ¼ 0.021) ( Figure 3A) ; among the PHIV hospitalized with HFpEF, the CV mortality rate was higher in the individuals taking a PI versus an NPI (33% vs. 15%; p ¼ 0.004) ( Figure 4A) ;
and among the PHIV hospitalized with HFbEF, the CV mortality rate was also higher in the individuals who were taking a PI versus an NPI (35% vs. 4%; p ¼ 0.01) ( Figure 5A ). There was an interaction present between the type of HF and the use of a PI-based regimen; however, PI use remained an independent predictor of CV mortality (Online Table 2 ). There was also no difference in CV mortality when different types of PIs were compared (Online Table 3 HIV-specific parameters (low nadir CD4 count or at index hospitalization and high VL); and low education level ( Table 4) . In a multivariable model, the following parameters remained independently associated with CV mortality rate: use of a PI-based Abbreviations as in Tables 1, 2 , and 4. Table 6 ). In a multivariable model among PHIV hospitalized with HFrEF, the following parameters remained independently associated with CV mortality rate: use of a PI-based regimen; history of CAD; increased PASP; decreased LVEF; low CD4 count (or high VL); and low education level ( Table 7) . Table 8 ). In a multivariable model in PHIV hospitalized with HFrEF, the following parameters remained independently associated with CV mortality rate: use of a PI-based regimen; history of CAD; cocaine use; increased PASP; low CD4 count (or high VL); low education level; and unemployment (Online Table 9 ).
DISCUSSION
We tested the associations between ritonavir-boosted PI regimens and cardiac structure and outcomes among PHIV with HF (Central Illustration). We report 4 key findings of broad clinical relevance to the care of patients with HIV and HF in our study: 1) 36% of the cohort of PHIV were receiving a PI-based regimen, Abbreviations as in Tables 1, 3 , and 4. as compared with a non-PI-based regimen, and these patients had higher rates of hyperlipidemia, diabetes mellitus, and CAD; 2) patients taking a PI had a higher In this study, ritonavir-boosted protease inhibitors were associated with increased cardiovascular mortality and 30-day heart failure (HF) readmission rates among persons with human immunodeficiency virus (HIV) with HF.
and an approximately 30% to 40% lower risk of incident HF compared with past users or never users of this drug. In that study, patients with HF were excluded, and the effect of PI regimens was not the focus; however, a significant proportion of the comparator group was prescribed a PI-based ART regimen.
As compared with uninfected controls, there is a marked increase in CV death among PHIV (13, 21, 22) .
For instance, Tseng et al. (22) completed a study of >2,800 individuals with HIV that showed a 4.5-fold greater risk of sudden cardiac death among PHIV.
In that cohort, those patients who died had a higher prevalence of CAD, cardiomyopathy, and HF.
Indeed, the prevalence of HF in that group was 30%
in patients who died as compared with 9% in those patients with HIV who did not die (22) . There are limited data on CV mortality in PHIV with HF (10,13). PHIV with HF who were taking a PI had increased rates of diabetes and CAD, both independent risk factors for mortality in HF (26, 27) . Additionally, other factors not addressed in this study may have played a role. Specifically, among PHIV, the increased CV risk is, in part, independent of traditional CV risk factors and is probably related to a persistent and heightened state of inflammation (28) (29) (30) . Inflammation is associated with worse outcomes in HF and CV disease, and the persistent inflammation in HIV may not be addressed using ART alone. studies (56% to 62%) (11, 20, 22) , and the viral suppression reported in our study is similar to that reported in a study by Hanna et al. (39) involving more than 7,196 PHIV from the same geographic location during the same time period (66%). Therefore, a potential explanation for the worse outcomes in PHIV is poor adherence to treatment for either HIV or HF.
In this retrospective study, adherence could not be assessed. However, we did test whether other surrogates of adherence were different between groups. In patients with HF who do not take HF medications, both heart rate and blood pressure are increased (40, 41) . In our study cohort, there was no difference in blood pressure and heart rate between the PHIV who had a PI as compared with the PHIV who had a non-PI-based regimen, a finding suggesting that compliance with HF medications may be similar between groups. Finally, even though we have applied the covariates in different multivariate models for independent prediction of outcomes, the possibility of residual confounding persists.
CONCLUSIONS
Being prescribed a ritonavir-boosted PI-based ART regimen was associated with dyslipidemia, a higher prevalence of CAD, increased PASP, and lower LVEF.
In follow-up, PHIV with HF who were prescribed a PIbased ART regimen were noted to be at twice the risk for 30-day HF admission and CV mortality, an effect independent of HIV control. Further research is needed to determine whether PI-based regimens, either individual regimens or as a class effect, contribute pathophysiologically to processes leading to worse outcomes in HF (e.g., myocardial fat and fibrosis) and whether these findings can be replicated in prospective cohorts. 
